AbbVie announces acquisition of Aliada Therapeutics, focusing on Alzheimer's disease and neuroscience pipeline
Acquiring Company
AbbVie Inc.
Acquired Company
Aliada Therapeutics
North ChicagoBostonManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaBiotechnologyDescription
AbbVie, a global biopharmaceutical company, has entered into a definitive agreement to acquire Aliada Therapeutics, a biotechnology company advancing CNS therapies using novel blood-brain barrier-crossing technology. This acquisition strengthens AbbVie's commitment to driving innovation in the neuroscience field, particularly in addressing unmet needs for patients with Alzheimer's disease and other neurological disorders.
Quick answer
AbbVie Inc. is acquiring Aliada Therapeutics, announced October 28, 2024. AbbVie Inc. is based in North Chicago, Illinois, United States.
- How much did AbbVie Inc. pay for Aliada Therapeutics?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Aliada Therapeutics based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. Aliada Therapeutics is based in Boston, Massachusetts, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie completes acquisition of Aliada Therapeutics to enhance neuroscience development (December 11, 2024)
- Celltrion acquires iQone Healthcare Switzerland to strengthen European expansion (November 14, 2024)
- Merck completes acquisition of investigational B-Cell depletion therapy, CN201, from Curon Biopharmaceutical (October 1, 2024)
- Boston Scientific completes acquisition of Axonics, Inc. to expand into sacral neuromodulation (November 15, 2024)
- Merck completes acquisition of Modifi Biosciences, Inc. to advance DNA modification enabled cancer therapeutics (October 23, 2024)
- Breeze Holdings Acquisition Corp. to merge with YD Biopharma Limited to revolutionize cancer prevention diagnostics (September 25, 2024)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Aliada Therapeutics?
Aliada Therapeutics was acquired by AbbVie Inc., based in North Chicago. The deal was reported on October 28, 2024. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Aliada Therapeutics?
AbbVie Inc.'s acquisition of Aliada Therapeutics was reported on October 28, 2024. AbbVie, a global biopharmaceutical company, has entered into a definitive agreement to acquire Aliada Therapeutics, a biotechnology company advancing CNS therapies using novel blood-brain barrier-crossing technology. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aliada Therapeutics do?
Biologics are transforming the treatment of numerous diseases, but many CNS diseases remain largely out of reach due to the challenge of crossing the blood-brain barrier and navigating the brain’s unique immune environment. It is privately held, operating in Biotechnology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.